I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

As it looks ahead to the potential launch of its sustained-delivery treatment Duravyu for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), EyePoint has tapped a new ...

Jalen Duren of Team USA Stars and Victor Wembanyama of Team World matched up during the 75th NBA All-Star Game. Ronald Martinez / Getty Images INGLEWOOD, Calif. — The NBA has gone global, so why ...

Both VOO and IVV track the S&P 500 with identical returns and expense ratios. IVV offers a slightly higher dividend yield and marginally heavier tech weighting. Liquidity, risk, and overall portfolio ...

AT&T cut its dividend in 2022, and its stock performance has remained flat since. Verizon has increased its dividend for 19 consecutive years, but the stock has struggled in the past five years. Which ...

Harrow, Inc. is experiencing explosive growth, driven by its success in branded pharmaceuticals, especially Vevye. Vevye, HROW's flagship dry eye drug, is projected to reach $100M in 2025 and $300M in ...

For Lynne, the first signs of dry eye disease came unexpectedly. Dry eye is increasingly common and can range from occasional or acute symptoms of dryness to a chronic condition called dry eye disease ...

I am writing this from my desk in St. Lucia with my girlfriend patiently waiting, so I will be brief. HROW reported earnings and lowered 2025 guidance to $270M to $280M from $280M+. This is utterly ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Dryness and end-of-day discomfort significantly ...

Julie Bowen has spent decades in front of the camera. Her roles in both movies and one of TV’s most beloved sitcoms have meant a lot of exposure to intense lighting and varied effects. But it wasn’t ...

High discontinuation rates in DED treatments indicate a need for more effective options, with 75% of patients stopping within 90 days. Immunomodulators are the most common first-line treatment, but ...